To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Neonatal encephalopathy (NE) is a clinical disorder of brain function that arises from various conditions impacting the central nervous system around the time of birth. Key symptoms include altered consciousness, respiratory depression, cranial nerve dysfunction, tone abnormalities, and seizures. The incidence of NE is estimated at 3 per 1,000 live births, with hypoxic–ischemic encephalopathy (HIE) accounting for approximately 1–1.5 per 1,000 live term births. Recent debates have centered around the definition and diagnosis of HIE, particularly concerning cerebral blood flow and oxygen delivery at birth. Identifying infants at high risk for evolving HIE is crucial, as therapeutic hypothermia, the only known treatment that can improve neurological outcomes, needs to be administered within 6 hours of birth. This chapter focuses on HIE as a distinct cause of NE, detailing its diagnosis and management, and discusses other conditions that may present with encephalopathy at different times post-delivery.
In 1958, the introduction of electronic fetal monitoring (EFM) dramatically changed labor and delivery practices by aiming to detect fetal heart rate (FHR) changes that could indicate fetal acidosis and prevent perinatal asphyxia. However, despite widespread adoption and numerous randomized controlled trials (RCTs) over the years, EFM has not demonstrated a significant impact on perinatal morbidity and mortality. Studies highlighted the minimal predictive value of nonreassuring FHR patterns for outcomes like cerebral palsy, alongside a high false positive rate. Critics argue that EFM may lead to an overdetection of nonreassuring patterns, contributing to the rising cesarean delivery rates in the United States. This chapter reviews the physiological basis of FHR patterns, the limitations of current monitoring practices, and explores ancillary tests that may enhance diagnostic accuracy. Additionally, it discusses the advancements in fetal ECG, pulse oximetry, and emerging machine learning technologies that could improve fetal assessment during labor.
Inborn errors of metabolism and abnormalities in many single genes related to neuronal function can have clinical, biochemical, and neuroradiologic features similar to those of neonatal encephalopathy caused by environmental factors, such as in-utero hypoxia, ischemia, inflammation, or infection. Both genetic disorders and neonatal encephalopathy secondary to environmental factors, such as hypoxic–ischemic encephalopathy (HIE) or fetal inflammatory response syndrome, may be associated with severe neurologic distress, metabolic acidosis, brain imaging abnormalities, and multiorgan system involvement. Although newborn screening using tandem mass spectrometry (MS/MS) can detect numerous metabolic disorders, many inborn errors of metabolism that present with HIE-like features will be missed, so specialized biochemical tests or next-generation gene sequencing studies are required in order to establish a diagnosis. Prompt diagnosis of an underlying genetic disorder not only may prevent mortality or significant morbidity but also may allow the clinician to provide the family with comprehensive genetic counseling.
Neonatal seizures are commonly encountered in the neonatal intensive care unit and are often a sign of underlying acute brain injury. Seizures in this age group have high rates of subclinical or electrographic only features, and thus continuous EEG monitoring is necessary for accurate and prompt diagnosis. Treatment of seizures is considered emergent, as ongoing seizures can amplify brain injury and worsen neurodevelopmental outcomes. Specific antiseizure medications used in this age group come from expert experience and consensus, but further clinical trials are needed to determine the safety and efficacy of newer medications that may be less toxic to the developing brain.
Hypoxemia poses a significant threat to fetal survival and development, often leading to neurodevelopmental disabilities including cerebral palsy or death. However, predicting and intervening in these cases remains challenging, despite advancements like therapeutic hypothermia. Abnormal fetal heart rate patterns provide only weak predictions of risk of acidemia and associated outcomes. Although severe metabolic acidemia correlates more strongly with neonatal outcomes, many infants with acute hypoxic–ischemic encephalopathy present with milder abnormalities, highlighting the complexity of hypoxic events. Modern studies indicate that only a fraction of cases of cerebral palsy are directly linked to intrapartum hypoxia-ischemia, and that a significant proportion of severe cases develop antenatally. This chapter will explore the mechanisms through which fetal adaptation to hypoxemia operates, circumstances that lead to failure of adaptation and subsequent brain injury, and the factors influencing the fetus’s ability to mitigate damage from hypoxia–ischemia.
Over the past 30 years, advancements in our understanding of brain development have transformed neonatal care. The establishment of NNCC as a distinct specialty, accredited in 2022, underscores the necessity for a multidisciplinary approach involving neonatology, neurology, neurophysiology, nursing, and neuroradiology. The first dedicated program was initiated in 2008, paving the way for improved brain monitoring techniques, such as amplitude-integrated electroencephalography, continuous EEG, and near-infrared spectroscopy, which facilitate timely identification and management of neurological conditions. Effective NNCC programs require substantial investment in equipment, staff training, and the development of tailored protocols to address the unique needs of NICU patients. Evidence suggests that focused brain care is crucial for all neonates, particularly those with conditions like hypoxic–ischemic encephalopathy and seizures. Integration of specialized care has demonstrated benefits, including reduced exposure to antiseizure medications and improved diagnostic accuracy. We highlight the essential components of NNCC programs and their role in optimizing neurodevelopmental outcomes for vulnerable infants.
SCN2A encodes a voltage-gated sodium channel (designated NaV1.2) vital for generating neuronal action potentials. Pathogenic SCN2A variants are associated with a diverse array of neurodevelopmental disorders featuring neonatal or infantile onset epilepsy, developmental delay, autism, intellectual disability and movement disorders. SCN2A is a high confidence risk gene for autism spectrum disorder and a commonly discovered cause of neonatal onset epilepsy. This remarkable clinical heterogeneity is mirrored by extensive allelic heterogeneity and complex genotype-phenotype relationships partially explained by divergent functional consequences of pathogenic variants. Emerging therapeutic strategies targeted to specific patterns of NaV1.2 dysfunction offer hope to improving the lives of individuals affected by SCN2A-related disorders. This Element provides a review of the clinical features, genetic basis, pathophysiology, pharmacology and treatment of these genetic conditions authored by leading experts in the field and accompanied by perspectives shared by affected families. This title is also available as Open Access on Cambridge Core.
KCNQ2 and KCNQ3 encode subunits (KV7.2, KV7.3) that combine to form a voltage-gated potassium ion (K+) channel responsible for generating an ionic current (M-current) important for controlling activity in the nervous system. Pathogenic variants in both genes are associated with a spectrum of genetic neurological disorders that feature epilepsy of variable severity and can be accompanied by debilitating impaired neurodevelopment. These two genes were among the first discovered causes of monogenic epilepsy, and are frequently identified in persons with early-life epilepsy. This Element provides a comprehensive review of the clinical features, genetic basis, pathophysiology, pharmacology and treatment of these prototypical neurological disorders accompanied by perspectives shared by affected families and scientists who have made seminal contributions to the field. This title is also available as Open Access on Cambridge Core.
Neonatal seizures are usually considered of epileptic origin, although some may be generated by non-epileptic mechanisms. Neonatal seizures may be classified by clinical features: focal clonic, focal tonic, myoclonic, spasms, generalized tonic and motor automatisms. The main categories of etiological factors of neonatal seizures include hypoxic- ischemic encephalopathy, central nervous system (CNS) infections, structural brain abnormalities, and metabolic disturbances. Early neuroimaging studies, particularly magnetic resonance imaging (MRI) with diffusion imaging, should show acute diffuse abnormalities consistent with hypoxia/ischemia. Some neonatal seizures result from long-standing disorders. These disorders include cerebral dysgenesis, neurocutaneous syndromes, genetic disorders, or very early onset epilepsy in association with well-defined epileptic syndromes. Clinical examination and seizure characterization are initial points of reference in the evaluation of infants suspected of early myoclonic encephalopathy (EME). Benzodiazepines are frequently used as alternative secondline antiepileptic drugs (AEDs), although more often they are given following phenobarbital and in place of phenytoin.
from
SECTION V
-
PEDIATRIC NEUROLOGICAL EMERGENCIES
By
Mont R. Roberts, Sparrow Healthcare System Sparow Hospital/MSU Emergency Medicine Residency Program Lansing, Michigan,
Rae R. Hanson, Midelfort Clinic Eau Claire, Wisconsin
The average age of childhood status epilepticus (SE) is under 3 years old. The acute management requires a planned treatment schedule and a specific time line. The duration of SE is the greatest risk to the patient; the longer SE lasts, the more difficult it is to treat. The three goals of treatment are to control seizures, to preserve vital functions, and to diagnose the underlying pathology. Absence SE, partial absence SE, or complex partial SE may present as nonconvulsive SE. Neonatal seizures occur in patients under 29 days old, and they are usually related to significant neurological disease. Pediatric patients are unique in that several characteristic epileptic syndromes have an age-dependent appearance, one or more characteristic seizure types, a natural history, and a prognosis. Some major syndromes include febrile seizures, infantile spasms, Lennox-Gastaut syndrome, and benign rolandic epilepsy (BRE).
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.